Company intelligence / Profile preview

Solid Therapeutics

Copenhagen, Denmarksolidtherapeutics.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Solid Therapeutics is developing novel dual-action therapeutics designed to disrupt solid tumor growth by impairing cancer cell survival and stimulating anti-tumor immunity. The company is early-stage, with no reported clinical results yet.[1]

Therapeutic areas: Oncology
Modalities: Dual-acting cancer therapeutics (likely biologics or small molecules, but not explicitly specified)
Industry: Biotech

Drug pipeline

1 asset

HCAR1 antagonist

Pre-clinical

Indications: Solid tumors, Breast cancer, Pancreatic cancer

Beyond the preview

Go deeper on Solid Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solid Therapeutics.

Explore the full profile